Chase Investment Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Chase Investment Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,490	Closed	-$520K	–	94
2019 Q4	$520K	Buy	+3,490	New	+$475K	0.26%	68
2018 Q4	–	Sell	-15,192	Closed	-$2.55M	–	104
2018 Q3	$2.55M	Buy	15,192 +12,037	+382%	+$2.07M	1.32%	32
2018 Q2	$543K	Sell	3,155 -80	-2%	-$13.1K	0.29%	60
2018 Q1	$488K	Buy	+3,235	New	+$475K	0.25%	62

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Chase Investment Counsel's JAZZ Position: Q1 2020 in Review

Chase Investment Counsel sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 3,490 shares — an estimated $520K sold.

Chase Investment Counsel first reported a position in JAZZ in Q1 2018 and held it in 4 quarters. The position peaked at $2.55M in Q3 2018. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Chase Investment Counsel reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Chase Investment Counsel sold 3,490 Jazz Pharmaceuticals shares in Q1 2020, an estimated $520K.
Chase Investment Counsel first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Chase Investment Counsel's Jazz Pharmaceuticals position peaked at $2.55M in Q3 2018.
408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Chase Investment Counsel's 13F filing for Q1 2020, filed 8 May 2020.